Find Locations
For hours, walk-ins and appointments.Unable to load global navigation.
Find Locations
For hours, walk-ins and appointments.The patient's age and gender must be included on the test request form.
3 - 5 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
For more information, please view the literature below.
LabCorp offers the leading HCV menu for complete care decisions
Serum
3.5 mL
2 mL
Red-top tube or gel-barrier tube
Separate serum from cells within two hours of collection, and transfer serum to a transfer tube.
Separate serum from cells within two hours of collection |
Separate serum from cells within two hours of collection, and transfer serum to a transfer tube. |
Specimen can be stored refrigerated at 2°C to 8°C for 72 hours and frozen at -70°C for seven days. Frozen samples are stable for one freeze/thaw cycle.
Temperature | Period |
---|---|
Room temperature | 72 hours (stability provided by manufacturer or literature reference) |
Refrigerated | 72 hours (stability provided by manufacturer or literature reference) |
Frozen | 7 days (stability provided by manufacturer or literature reference) |
Freeze/thaw cycles | Stable x1 (stability provided by manufacturer or literature reference) |
Patient should be fasting for at least eight hours.
Gross hemolysis; gross lipemia; improper labeling; nonfasting specimen; patient younger than 14 years of age
Assessment of liver status following a diagnosis of HCV. Baseline determination of liver status before initiating HCV therapy. Posttreatment assessment of liver status six months after completion of therapy. Noninvasive assessment of liver status in patients who are at increased risk of complications from a liver biopsy.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.
See individual test components.
See tables.
Fibrosis Stage (FibroTest) | Range |
---|---|
F0−No fibrosis | 0.00−0.21 |
F0−F1 | >0.21−0.27 |
F1−Portal fibrosis | >0.27−0.31 |
F1−F2 | >0.31−0.48 |
F2−Bridging fibrosis with few septa | >0.48−0.58 |
F3−Bridging fibrosis with many septa | >0.58−0.72 |
F3−F4 | >0.72−0.74 |
F4−Cirrhosis | >0.74−1.00 |
Activity Stage (ActiTest) | Range |
---|---|
A0−No activity | 0.00−0.17 |
A0−A1 | >0.17−0.29 |
A1−Minimal activity | >0.29−0.36 |
A1−A2 | >0.36−0.52 |
A2−Moderate activity | >0.52−0.60 |
A2−A3 | >0.60−0.63 |
A3−Severe activity | >0.63−1.00 |
See tables.
|
||||||||||||||||||||||||||||||||||
See tables.
|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf